ClinicalTrials.gg
RecruitingNCT06868069HypoPHrailUpdated Mar 30, 2026

Study on Blood Pressure Variability and Frailty in the Older People

An observational study in Hypertension and Old Age, sponsored by Istituto Auxologico Italiano. Recruiting at 1 site in Italy. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2026-03-30.

Sponsored by Istituto Auxologico Italiano · Observational

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
220
Ages
75 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Hypertension by Istituto Auxologico Italiano — 5 open to participants now, 5 under way, none of them phase 3. Hypertension · Istituto Auxologico Italiano.

Started
2024
with 1 other
Observational
7 of 14
3 open now
Registered
14th of 14
by date

Among the 14 studies in Hypertension by Istituto Auxologico Italiano, this one is one of 2 that started in 2024, is one of 7 observational ones, and was the 14th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

5 of the 14 studies in Hypertension by Istituto Auxologico Italiano are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 75 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Hypertension by Istituto Auxologico Italiano, or all of them as a file.
02

Study summary

Observational prospective single-center, non-profit study. Primary objective of the study: To determine if the hypotensive phenotype, defined as one episode of daytime systolic blood pressure (SBP) \<90 mmHg (or two episodes of daytime SBP \<90 mmHg, if mean 24 h SBP is \<125 mmHg) detected at Ambulatory Blood Pressure Monitoring (ABPM) is associated with adverse events at follow up (death, hospitalization, falls, emergency room admission for uncontrolled hypertension, major cardiovascular events)

Read the detailed description

Observational prospective single-center, non-profit study. Primary objective of the study: To determine if the hypotensive phenotype, defined as one episode of daytime systolic blood pressure (SBP) \<90 mmHg (or two episodes of daytime SBP \<90 mmHg, if mean 24 h SBP is \<125 mmHg) detected at Ambulatory Blood Pressure Monitoring (ABPM) is associated with adverse events at follow up (death, hospitalization, falls, emergency room admission for uncontrolled hypertension, major cardiovascular events)

Secondary objectives of the study:

  • To examine the association between home Blood Pressure Variability (BPV) and frailty, assessed using various tools for assessing frailty
  • To examine the association between short term BPV and adverse events at follow up (death, hospitalization, falls, emergency room admission for uncontrolled hypertension, major cardiovascular events)
  • To determine the prevalence of hypotensive phenotype according to frailty status in hypertensive individuals.
03

Conditions studied

  • Hypertension
  • Old Age

Keywords

  • Blood pressure variability
  • Frailty
04

Who can participate

Ages eligible
75 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Elderly hypertensive patients who are enrolled at the Hypertension Centre of Istituto Auxologico italiano IRCCS

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 75 years
  • Diagnosis of hypertension according to the criteria of the European Society of Cardiology guidelines [Williams 2018]
  • Consent of the patient (or legal representative) to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Refusal of the patient or his/her legal representative
  • of less than 6 months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
220 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with hypertension, aged 75 years and older

    Diagnostic Test: Diagnostic tests and questionnaires

Interventions

  • Diagnostic testDiagnostic tests and questionnaires

    Assessment of office blood pressure, orthostatic hypotension, 24-hour ambulatory blood pressure, frailty

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events

    Adverse events at follow up (death, hospitalization, falls, emergency room admission for uncontrolled hypertension, major cardiovascular events)

    Time frame: At 24 months of follow-up

  2. Prevalence of hypotensive phenotype

    Hypotensive phenotype, defined as one episode of daytime systolic blood pressure (SBP) \<90 mmHg (or two episodes of daytime SBP \<90 mmHg, if mean 24 h SBP is \<125 mmHg)

    Time frame: At baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Jul 2027, 36 months after the start.

Of 348 non-industry observational studies under Hypertension, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 111. This study's planned 36 months is below that.

Counting every sponsor, half of 429 studies reached it within 38 months; a quarter within 17 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2025
First posted
Mar 10, 2025
StartActual
Jul 15, 2024
Primary completionEst.
Jul 15, 2027
CompletionEst.
Jul 15, 2027
Last update
Mar 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06868069
Responsible party
Sponsor
First posted
Mar 10, 2025
Start date
Jul 15, 2024
Primary completion
Jul 15, 2027 (estimated)
Completion
Jul 15, 2027 (estimated)
Last update
Mar 30, 2026

Study contacts

Alessandro Croce, MD
Contact
a.croce@auxologico.it
+3902619111
Luca Grappiolo, Dr.
Contact
luca.grappiolo@auxologico.it
+3902619111 ext. 2894

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion